Annals of Nuclear Medicine

, Volume 19, Issue 5, pp 355–365 | Cite as

Current status of cancer therapy with radiolabeled monoclonal antibody

  • Noboru Oriuchi
  • Tetsuya Higuchi
  • Hirofumi Hanaoka
  • Yasuhiko Iida
  • Keigo Endo


Molecular targeting therapy has become a relevant therapeutic strategy for cancer. There are several monoclonal antibodies used for the treatment of malignant tumors. Radioimmunoconjugate is composed of antibody and radionuclide showing a synergistic effect of radiation and immunemediated cellular toxicity and thereby enabling increased efficacy and minimizing toxicity. Radioimmunotherapy using131I- and90Y-labeled anti-CD20 monoclonal antibodies is now indicated for the treatment of patients with CD20 antigen-expressing relapsed or refractory, low-grade or transformed non-Hodgkin’s lymphoma (NHL), including patients who are refractory to anti-CD20 monoclonal antibody (rituximab) therapy in the United States. It has been exhibiting favorable anti-tumor efficacy in patients with NHL as compared with rituximab. Myelosuppression is the main side effect associated with the radioimmunotherapy but is usually reversible, and nonhematologic adverse reactions are mild to moderate.

Following the impressive results of therapy using radiolabeled monoclonal antibodies for NHL, radioimmunotherapy for solid tumors has been examined; however, the results were unfavorable and did warrant further clinical trials as a single agent. Future studies on radioimmunotherapy for solid tumors should focus on the new strategies of targeting such as locoregional administration for intraperitoneal dissemination, and combination therapy with chemotherapy or cytostatic therapy. Although radioimmunotherapy for NHL has shown excellent results comparable to aggressive chemotherapy without severe adverse effects, additional clinical trials should be performed to define the proper role of radioimmunoconjugates as a relevant strategy for cure of NHL.

Key words

monoclonal antibody radioimmunotherapy radioimmunoconjugate malignant lymphoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity.Nature 1975; 256:495–497.PubMedCrossRefGoogle Scholar
  2. 2.
    McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.J Clin Oncol 1998; 16:2825–2833.PubMedGoogle Scholar
  3. 3.
    Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cellsin vivo by a chimeric mouse human monoclonal antibody to CD20.Blood 1994; 83:435–445.PubMedGoogle Scholar
  4. 4.
    Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies.Blood 1998; 91:1644–1652.PubMedGoogle Scholar
  5. 5.
    Tutt AL, French RR, Illidge TM, Honeychurch J, McBride HM, Penfold CA, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.J Immunol 1998; 161:3176–3185.PubMedGoogle Scholar
  6. 6.
    Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma.Breast Cancer Res Treat 1994; 29:127–138.PubMedCrossRefGoogle Scholar
  7. 7.
    Ritter G, Cohen LS, Williams Jr C, Richards EC, Old LJ, Welt S. Serological Analysis of Human Anti-Human Antibody Responses in Colon Cancer Patients Treated with Repeated Doses of Humanized Monoclonal Antibody A33.Cancer Res 2001 ; 61:6851–6859.PubMedGoogle Scholar
  8. 8.
    Tomizuka K, Shinohara T, Yoshida H, Uejima H, Ohguma A, Tanaka S, et al. Double trans-chromosomic mice: maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies.Proc Natl Acad Sci USA 2000; 97:722–727.PubMedCrossRefGoogle Scholar
  9. 9.
    Ishida I, Tomizuka K, Yoshida H, Tahara T, Takahashi N, Ohguma A, et al. Production of human monoclonal and polyclonal antibodies in TransChromo animals.Cloning Stem Cells 2002; 4:91–102.PubMedCrossRefGoogle Scholar
  10. 10.
    Winter G, Griffiths AD, Hawkins RE, Hoogenboom HR. Making antibodies by phage display technology.Annu Rev Immunol 1994; 12:33–455.CrossRefGoogle Scholar
  11. 11.
    Tsurushita N, Park M, Pakabunto K, Ong K, Avdalovic A, Fu H, et al. Humanization of a chicken anti-IL-12 monoclonal antibody.J Immunol Methods 2004; 295:9–19.PubMedCrossRefGoogle Scholar
  12. 12.
    McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides.Eur J Nucl Med 1998; 25:1341–1351.PubMedCrossRefGoogle Scholar
  13. 13.
    Macklis RM, Kinsey BM, Kassis AI, Ferrara JL, Atcher RW, Hines JJ, et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates.Science 1988; 240:1024–1026.PubMedCrossRefGoogle Scholar
  14. 14.
    Behr TM, Behe M, Lohr M, Sgouros G, Angerstein C, Wehrmann E, et al. Therapeutic advantages of Auger electron- over beta-emitting radiometals or radioiodine when conjugated to internalizing antibodies.Eur J Nucl Med 2000; 27:753–765.PubMedCrossRefGoogle Scholar
  15. 15.
    Burke JM, Jurcic JG, Scheinberg DA. Radioimmunotherapy for acute leukemia.Cancer Control 2002; 9:106–113.PubMedGoogle Scholar
  16. 16.
    Juweid M, Sharkey RM, Swayne LC, Griffiths GL, Dunn R, Goldenberg DM. Pharmacokinetics, dosimetry and toxicity of rhenium-188-labeled anti-carcinoembryonic antigen monoclonal antibody, MN-14, in gastrointestinal cancer.J Nucl Med 1998; 39:34–42.PubMedGoogle Scholar
  17. 17.
    Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, et al. Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.J Nucl Med 1997; 38:858–870.PubMedGoogle Scholar
  18. 18.
    Juweid ME, Sharkey RM, Behr T, Swayne LC, Dunn R, Siegel J, et al. Radioimmunotherapy of patients with small-volume tumors using iodine-131-labeled anti-CEA monoclonal antibody NP-4 F(ab’)2.J Nucl Med 1996; 37:1504–1510.PubMedGoogle Scholar
  19. 19.
    Behr TM, Liersch T, Greiner-Bechert L, Griesinger F, Behe M, Markus PM, et al. Radioimmunotherapy of small-volume disease of metastatic colorectal cancer.Cancer 2002; 94(4 Suppl); 1373–1381.PubMedCrossRefGoogle Scholar
  20. 20.
    Wong JYC, Chu DZ, Yamauchi DM, Williams LE, Liu A, Wilczynski S, et al. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.Clin Cancer Res 2000; 6:3855–3863.PubMedGoogle Scholar
  21. 21.
    Wu AM, Yazaki PJ, Tsai S, Nguyen K, Anderson AL, McCarthy DW, et al. High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.Proc Natl Acad Sci USA 2000; 97:8495–8500.PubMedCrossRefGoogle Scholar
  22. 22.
    Begent RH, Ledermann JA, Green AJ, Bagshawe KD, Riggs SJ, Searle F, et al. Antibody distribution and dosimetry in patients receiving radiolabelled antibody therapy for colorectal cancer.Br J Cancer 1989; 60:406–412.PubMedGoogle Scholar
  23. 23.
    Begent RH, Verhaar MJ, Chester KA, Casey JL, Green AJ, Napier MP, et al. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library.Nat Med 1996; 2:979–984.PubMedCrossRefGoogle Scholar
  24. 24.
    Wong JY, Shibata S, Williams LE, Kwok CS, Liu A, Chu DZ, et al. A Phase I trial of90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.Clin Cancer Res 2003; 9:5842–5852.PubMedGoogle Scholar
  25. 25.
    Murray JL, Macey DJ, Kasi LP, Rieger P, Cunningham J, Bhadkamkar V, et al. Phase II radioimmunotherapy trial with131I-CC49 in colorectal cancer.Cancer 1994; 73(suppl):1057–1066.PubMedCrossRefGoogle Scholar
  26. 26.
    Macey DJ, Grant EJ, Kasi L, Rosenblum MG, Zhang HZ, Katz RL, et al. Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial.Clin Cancer Res 1997; 3:1547–1555.PubMedGoogle Scholar
  27. 27.
    Meredith RF, Khazaeli MB, Macey DJ, Grizzle WE, Mayo M, Schlom J, et al. Phase II study of interferon-enhanced131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer.Clin Cancer Res 1999; 5(suppl):3254s-3258s.PubMedGoogle Scholar
  28. 28.
    Meredith RF, Khazaeli MB, Plott WE, Grizzle WE, Liu T, Schlom J, et al. Phase II study of dual131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.Clin Cancer Res 1996; 2:1811–1818.PubMedGoogle Scholar
  29. 29.
    Meredith RF, Khazaeli MB, Plott WE, SA, Wheeler RH, Brady LW, et al. Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.J Nucl Med 1995; 36:2229–2233.PubMedGoogle Scholar
  30. 30.
    Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham MC, et al. Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody.J Nucl Med 1996; 37:1052–1057.PubMedGoogle Scholar
  31. 31.
    Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, et al. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.J Clin Oncol 1996; 14:1787–1797.PubMedGoogle Scholar
  32. 32.
    Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with177Lu-CC49: a phase I/II study.Gynecol Oncol 1997; 65:94–101.PubMedCrossRefGoogle Scholar
  33. 33.
    Meredith RF, Alvarez RD, Partridge EE, Khazaeli MB, Lin CY, Macey DJ, et al. Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study.Cancer Biother Radiopharm 2001; 16:305–315.PubMedCrossRefGoogle Scholar
  34. 34.
    Alvarez RD, Huh WK, Khazaeli MB, Meredith RF, Partridge EE, Kilgore LC, et al. A phase I study of combined modality (90)yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer.Clin Cancer Res 2002; 8:2806–2811.PubMedGoogle Scholar
  35. 35.
    Colcher D, Bird R, Roselli M, Hardman KD, Johnson S, Pope S, et al.In vivo tumor targeting of a recombinant single-chain antigen-binding protein.J Natl Cancer Inst 1990; 82:1191–1197.PubMedCrossRefGoogle Scholar
  36. 36.
    Adams GP, McCartney JE, Tai MS, et al. Highly specificin vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv.Cancer Res 1993; 53:4026–4034.PubMedGoogle Scholar
  37. 37.
    Yokota T, Milenic DE, Whitlow M, Wood JF, Hubert SL, Schlom J. Micro autoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms.Cancer Res 1993; 53:3776–3783.PubMedGoogle Scholar
  38. 38.
    Larson SM, El-Shirbiny AM, Divgi CR, Sgouros G, Finn RD, Tschmelitsch J, et al. Single chain antigen binding protein (scFv CC49): first human studies in colorectal carcinoma metastatic to liver.Cancer 1997; 80:2458–2468.PubMedCrossRefGoogle Scholar
  39. 39.
    Chang CH, Sharkey RM, Rossi EA, Karacay H, McBride W, Hansen HJ, et al. Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies.Mol Cancer Ther 2002; 1:553–563.PubMedGoogle Scholar
  40. 40.
    Sharkey RM, McBride WJ, Karacay H, Chang K, Griffiths GL, Hansen HJ, et al. A universal pretargeting system for cancer detection and therapy using bispecific antibody.Cancer Res 2003; 63:354–363.PubMedGoogle Scholar
  41. 41.
    Hnatowich DJ, Virzi F, Rusckowski M. Investigations of avidin and biotin for imaging applications.J Nucl Med 1987; 28:1294–1302.PubMedGoogle Scholar
  42. 42.
    Axworthy DB, Reno JM, Hylarides MD, Mallett RW, Theodore LJ, Gustavson LM, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.Proc Natl Acad Sci USA 2000; 97:1802–1807.PubMedCrossRefGoogle Scholar
  43. 43.
    Breitz HB, Weiden PL, Beaumier PL, Axworthy DB, Seiler C, Su FM, et al. Clinical optimization of pretargeted radioimmunotherapy with antibody-streptavidin conjugate and90Y-DOTA-biotin.J Nucl Med 2000; 41:131–140.PubMedGoogle Scholar
  44. 44.
    Paganelli G, Riva P, Deleide G, Clivio A, Chiolerio F, Scassellati GA, et al.In vivo labeling of biotinylated monoclonal antibodies by radioactive avidin: a strategy to increase tumor radiolocalization.Int J Cancer 1988; 2(Suppl):121–125.CrossRefGoogle Scholar
  45. 45.
    Wiseman GA, White CA, Stabin M, Dunn WL, Erwin W, Dahlbom M, et al. Phase I/II90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin’s lymphoma.Eur J Nucl Med Mol Imag 2000; 27:766–777.CrossRefGoogle Scholar
  46. 46.
    Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy.Clin Cancer Res 2004; 10:7792–7798.PubMedCrossRefGoogle Scholar
  47. 47.
    DeNardo GL, DeNardo SJ, Lamborn KR, Goldstein DS, Levy NB, Lewis JP, et al. Low-dose, fractionated radioimmunotherapy for B-cell malignancies using131I-Lym-l antibody.Cancer Biother Radiopharm 1998; 13:239–254.PubMedCrossRefGoogle Scholar
  48. 48.
    O’Donnell RT, Shen S, Denardo SJ, Wun T, Kukis DL, Goldstein DS, Denardo GL. A phase I study of90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin’s lymphoma.Anticancer Res 2000; 20:3647–3655.PubMedGoogle Scholar
  49. 49.
    Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen.J Immunol 1980; 125:1678–1685.PubMedGoogle Scholar
  50. 50.
    Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin’s Lymphoma.J Clin Oncol 1999; 17:3793–3803.PubMedGoogle Scholar
  51. 51.
    Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy versus Rituximab Immunotherapy for Patients with Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma.J Clin Oncol 2002; 20:2453–2463.PubMedCrossRefGoogle Scholar
  52. 52.
    Wiseman GA, Gordon LI, Multani PS, Witzig TE, Spies S, Bartlett NL, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.Blood 2002; 99:4336–4342.PubMedCrossRefGoogle Scholar
  53. 53.
    Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximabrefractory follicular non-Hodgkin’s lymphoma.J Clin Oncol 2002; 20:3262–3269.PubMedCrossRefGoogle Scholar
  54. 54.
    Gordon LI, Molina A, Witzig TE, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study.Blood 2004; 103:4429–4431.PubMedCrossRefGoogle Scholar
  55. 55.
    Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, et al. Iodine-131 -anti-B 1 radioimmunotherapy for B-cell lymphoma.J Clin Oncol 1996; 14:1974–1981.PubMedGoogle Scholar
  56. 56.
    Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.Blood 2000; 96:1259–1266.PubMedGoogle Scholar
  57. 57.
    Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas.J Clin Oncol 2001; 19:3918–3928.PubMedGoogle Scholar
  58. 58.
    Dillman RO. Radiolabeled Anti-CD20 Monoclonal Antibodies for the Treatment of B-Cell Lymphoma.J Clin Oncol 2002; 20:3545–3557.PubMedCrossRefGoogle Scholar
  59. 59.
    Wahl RL, Kroll S, Zasadny KR. Patient-specific whole-body dosimetry: principles and a simplified method for clinical implementation.J Nucl Med 1998; 39:14S-20S.PubMedGoogle Scholar
  60. 60.
    Rutar FJ, Augustine SC, Colcher D, Siegel JA, Jacobson DA, Tempero MA, et al. Outpatient Treatment with131I-Anti-Bl Antibody: Radiation Exposure to Family Members.J Nucl Med 2001 ; 42:907–915.PubMedGoogle Scholar
  61. 61.
    Harwood SJ, Gibbons LK, Goldner PJ, Webster WB, Carroll RG. Outpatient radioimmunotherapy with Bexxar: Closed, clean air reservoir minimizes personnel radiation exposure.Cancer 2002; 94:1358–1362.PubMedCrossRefGoogle Scholar
  62. 62.
    Davis TA, Kaminski MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz A, et al. The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy.Clin Cancer Res 2004; 10:7792–7798.PubMedCrossRefGoogle Scholar
  63. 63.
    Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al.131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma.N Engl J Med 2005; 352:441–149.PubMedCrossRefGoogle Scholar
  64. 64.
    Weiden PL, Breitz HB, Press O, Appelbaum JW, Bryan JK, Gaffigan S, et al. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin’s lymphoma (NHL): initial phase I/II study results.Cancer Biother Radiopharm 2000; 15:15–29.PubMedCrossRefGoogle Scholar
  65. 65.
    Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma.Blood 2004; 104:227–236.PubMedCrossRefGoogle Scholar
  66. 66.
    Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, et al. German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia.Blood 2001; 98:1326–1331.PubMedCrossRefGoogle Scholar
  67. 67.
    Lin TS, Lucas MS, Byrd JC. Rituximab in B-cell chronic lymphocytic leukemia.Semin Oncol 2003; 30:483–492.PubMedCrossRefGoogle Scholar
  68. 68.
    Lin TS, Flinn IW, Lucas MS, Porcu P, Sickler J, Moran ME, et al. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.Leukemia 2005 (in press).Google Scholar
  69. 69.
    Linenberger ML. CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance.Leukemia 2005; 19:176–182.PubMedCrossRefGoogle Scholar
  70. 70.
    DiJoseph JF, Goad ME, Dougher MM, Boghaert ER, Kunz A, Hamann PR, et al. Potent and specific antitumor efficacy of CMC-544, a CD22-targeted immunoconjugate of calicheamicin, against systemically disseminated B-cell lymphoma.Clin Cancer Res 2004; 10:8620–8629.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Noboru Oriuchi
    • 1
  • Tetsuya Higuchi
    • 1
  • Hirofumi Hanaoka
    • 2
  • Yasuhiko Iida
    • 2
  • Keigo Endo
    • 1
  1. 1.Department of Diagnostic Radiology and Nuclear MedicineGunma University Graduate School of MedicineMaebashiJapan
  2. 2.Department of Bioimaging Information AnalysisGunma University Graduate School of MedicineJapan

Personalised recommendations